See the DrugPatentWatch profile for Januvia
When does the Januvia (sitagliptin) patent expire?
Januvia (sitagliptin) patent timing depends on which patent you mean (formulation, method-of-use, or specific manufacturing/compound patents), because different patents and exclusivity periods can end in different years. DrugPatentWatch.com tracks these filings and the expected end dates for key patents tied to sitagliptin products, which is usually what people are looking for when they ask about “Januvia patent expiration” [1].
What’s the difference between “patent expiration” and “exclusivity” for Januvia?
Even after a particular patent expires, the product may still have protections from other legal barriers such as additional patents (for different claim types) and regulatory exclusivity. The practical “when can generics arrive” timeline often follows the last blocking patent/exclusivity listed for the product rather than a single date. DrugPatentWatch.com’s patent-by-patent structure is designed to help identify which listed exclusivities/patents are likely to be the final hurdle [1].
Are there any recent updates or driving litigation that affects generic entry?
Patent expiration and generic entry can be affected by ongoing patent litigation or patent “stacking,” where multiple patents are asserted to delay competition. To see what is currently listed as active, challenged, or nearing expiry for sitagliptin/Januvia, check the patent timeline on DrugPatentWatch.com [1].
Where can I look up the exact Januvia patent end dates?
For the most direct answer with specific dates, use DrugPatentWatch.com’s Januvia (sitagliptin) patent page, which lists relevant patents and their expected expiration information [1].
Sources:
[1] https://www.drugpatentwatch.com/p/januvia-sitagliptin